The $290M capital raise removes near-term financing risk and funds the pipeline through key Phase I data readouts in 2027. Monitor for AN4035 first-patient dosing in H2 2026 and AN9025 initial data in H1 2027 as the next major catalysts. The de-prioritization of AN4005 is a modest pipeline narrowing but not a negative given the focus on higher-value RAS assets.
Price Chart
Executive Summary
Adlai Nortye reported H1 2026 financial results showing a 70.9% reduction in net loss to $5.3M, driven by $13.1M in initial revenue from the AN9025 license deal and lower R&D spend. The company raised $290M in two oversubscribed private placements, boosting cash to $231.9M from $8.1M, and is advancing its pan-RAS pipeline with Phase I data expected in 2027. The massive cash infusion and first revenue generation are material positives, but the company remains pre-commercial with no near-term catalysts beyond early-stage trial updates.
Key Facts
- Net loss decreased 70.9% to $5.3M for H1 2026 from $18.3M in H1 2025
- Revenue of $13.1M in H1 2026 vs nil in H1 2025, from AN9025 license agreement with Jiangsu Aosaikang
- Cash and short-term investments of $231.9M as of June 30, 2026, up from $8.1M at Dec 31, 2025
- Raised $140M in Feb 2026 and $150M in Apr 2026 via oversubscribed private placements
- Shares outstanding increased from 120.0M to 193.2M (Class A + Class B) in H1 2026
- AN9025 Phase I QD and QW arms enrolling; initial data expected H1 2027
- AN4035 received HREC approval in Australia for Phase I; first patient dosing expected H2 2026
- AN4005 development de-prioritized as monotherapy; open for collaboration
- R&D expenses decreased 4% to $14.6M; G&A expenses increased 43.1% to $5.8M
- Cash used in operations was $15.4M, roughly flat vs $15.1M in prior year period
Financial Impact
Cash runway extended significantly with $231.9M in liquidity; first revenue of $13.1M from AN9025 license; net loss reduced to $5.3M
Risk Factors
- Significant shareholder dilution from 73M+ new shares issued in H1 2026
- All pipeline assets are early-stage (Phase I); no approved products or near-term commercial revenue
- AN4005 de-prioritization reduces pipeline optionality; collaboration may not materialize
- Clinical trial execution risk for AN9025 and AN4035; data readouts not expected until 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-089447 |
| Document: 0001213900-26-089447-index-headers.html | 0001213900-26-089447 |
| Document: 0001213900-26-089447-index.html | 0001213900-26-089447 |
| Document: 0001213900-26-089447.txt | 0001213900-26-089447 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $12.09 $10.58 | ▼ −12.49% | ▼ −11.48% | $10.58 (−12.49%) |
Oct 15, 2026 12d ago | Press Release | $12.09 $10.58 | ▼ −12.49% | ▼ −11.48% | $10.58 (−12.49%) |
Sep 30, 2026 27d ago | 6-K | $16.00 $14.05 | ▼ −12.19% | ▼ −14.10% | $10.58 (−33.88%) |
Sep 30, 2026 27d ago | 6-K | $16.00 $14.05 | ▼ −12.19% | ▼ −14.10% | $10.58 (−33.88%) |
Sep 16, 2026 5w ago | EFFECT | $15.52 $15.75 | ▲ +1.48% | ▼ −0.34% | $10.58 (−31.83%) |
Aug 26, 2026 8w ago | 6-K | $15.06 $13.86 | ▼ −8.00% | ▼ −7.88% | $10.58 (−29.75%) |
Aug 19, 2026 9w ago | 6-K | $14.33 $15.06 | ▲ +5.09% | ▲ +5.48% | $10.58 (−26.17%) |
Aug 14, 2026 10w ago | 6-K | $13.25 $13.70 | ▲ +3.40% | ▲ +4.76% | $10.58 (−20.15%) |
Aug 14, 2026 10w ago | Press Release | $13.25 $13.70 | ▲ +3.40% | ▲ +4.76% | $10.58 (−20.15%) |
Aug 3, 2026 12w ago | 6-K | $12.99 $13.23 | ▲ +1.85% | ▼ −0.18% | $10.58 (−18.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers